Wall Street Zen lowered shares of Climb Bio (NASDAQ:CLYM – Free Report) from a hold rating to a sell rating in a research note released on Sunday morning,Wall Street Zen reports.
Several other analysts have also recently issued reports on CLYM. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research note on Thursday, October 15th. Truist Financial upped their price target on shares of Climb Bio from $17.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Mizuho raised Climb Bio to a “strong-buy” rating in a research note on Wednesday, September 16th. B. Riley Financial reissued a “buy” rating on shares of Climb Bio in a research report on Friday, September 4th. Finally, Royal Bank Of Canada started coverage on Climb Bio in a research note on Monday, August 3rd. They issued an “outperform” rating and a $23.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $28.14.
Get Our Latest Research Report on Climb Bio
Climb Bio Stock Performance
NASDAQ:CLYM opened at $10.36 on Friday. The stock has a market cap of $608.53 million, a P/E ratio of -12.63 and a beta of 0.01. The stock’s 50-day moving average is $11.58 and its 200-day moving average is $10.63. Climb Bio has a 1-year low of $1.63 and a 1-year high of $18.33.
Climb Bio (NASDAQ:CLYM – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. As a group, equities analysts forecast that Climb Bio will post -0.75 EPS for the current year.
Insider Activity
In other news, Director Stephen Thomas sold 100,000 shares of Climb Bio stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total transaction of $1,367,000.00. Following the transaction, the director owned 467,969 shares in the company, valued at $6,397,136.23. The trade was a 17.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.60% of the stock is owned by company insiders.
Institutional Investors Weigh In On Climb Bio
A number of hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new position in shares of Climb Bio in the 3rd quarter valued at $6,406,000. Empowered Funds LLC purchased a new stake in Climb Bio in the third quarter valued at approximately $265,000. First Trust Advisors LP purchased a new stake in Climb Bio in the third quarter valued at approximately $490,000. State Street Corp boosted its holdings in shares of Climb Bio by 34.7% in the third quarter. State Street Corp now owns 1,850,010 shares of the company’s stock valued at $21,220,000 after acquiring an additional 476,466 shares during the period. Finally, Fisher Asset Management LLC acquired a new stake in shares of Climb Bio in the third quarter valued at approximately $505,000. Institutional investors and hedge funds own 69.76% of the company’s stock.
Climb Bio Company Profile
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and Fc?RIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Read More
- Five stocks we like better than Climb Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
